The effects of incubation delays on the accuracy of the QuantiFERON-TB gold in-tube assay (QFT-GIT) were measured. Compared to immediate incubation, 6- and 12-hour delays resulted in positive-to-negative reversion rates of 19% (5/26) and 22% (5/23), respectively. These findings underscore the need for standardizing QFT-GIT preanalytical practices.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147723PMC
http://dx.doi.org/10.1128/JCM.01136-11DOI Listing

Publication Analysis

Top Keywords

quantiferon-tb gold
8
gold in-tube
8
in-tube assay
8
preanalytical delay
4
delay reduces
4
reduces sensitivity
4
sensitivity quantiferon-tb
4
assay detection
4
detection latent
4
latent tuberculosis
4

Similar Publications

Evaluation of QuantiFERON-TB Gold for the Diagnosis of Infection in HTLV-1-Infected Patients.

Viruses

November 2024

Laboratório Avançado de Saúde Pública, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (Fiocruz-BA), Salvador 40296-710, Bahia, Brazil.

Human T-cell leukemia virus type 1 (HTLV-1) is associated with an increased risk of tuberculosis (TB). This study aimed to evaluate the performance of the QuantiFERON-TB Gold (QFT) test for the diagnosis of (MTB) infection in HTLV-1-infected individuals. HTLV-1-infected participants were divided into four groups: HTLV-1-infected individuals with a history of tuberculosis (HTLV/TB), individuals with positive HTLV and tuberculin skin tests (HTLV/TST+) or negative TST (HTLV/TST-), and HTLV-1-negative individuals with positive TST results (HN/TST+).

View Article and Find Full Text PDF

Predictive Markers of Incident Tuberculosis in Close Contacts in Brazil and India.

J Infect Dis

January 2025

Programa de Pós-graduação em Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.

There are insufficient predictors of progression to tuberculosis among contacts. A case-control study within RePORT-Brazil matched 20 QuantiFERON-positive progressors and 40 non-progressors by sex, age, and exposure duration. Twenty-nine cytokines were measured by Luminex in QuantiFERON-TB Gold Plus supernatants collected at baseline and evaluated using machine learning for tuberculosis prediction.

View Article and Find Full Text PDF

Discordance of 3rd and 4th generation QuantiFERON-TB Gold assays by pregnancy stages in India.

J Clin Tuberc Other Mycobact Dis

February 2025

Weill Cornell Medicine, Center for Global Health, 402 East 67th Street, 2nd Floor, New York, NY 10065, USA.

Background: Pregnancy and HIV affect CD4+ T lymphocytes and impact performance of QuantiFERON-TB Gold (QFT). We compared the results of QFT with QuantiFERON-TB Gold Plus (QFT-Plus), which also measures CD8+ responses to TB antigens, during pregnancy and postpartum.

Methods: We screened 516 pregnant women for TB infection (TBI) with IGRA.

View Article and Find Full Text PDF

Introduction: Identifying tuberculosis infection (TBI) using interferon-gamma release assays (IGRAs) is a primary component of clinical and public health efforts to prevent pediatric tuberculosis. Pediatric data comparing the two IGRAs in the United States are very limited. We compared the performance of the two IGRAs among a large pediatric cohort tested for TBI and assessed whether discordance might be due to quantitative results close to test cut-off values.

View Article and Find Full Text PDF

Unlabelled: Urgent improvements in the diagnosis and management of infection are required to reach End TB goals. Conventional interferon-gamma release assays (IGRAs), such as QuantiFERON-TB Gold Plus (QFT-Plus), require substantial laboratory infrastructure and large blood volumes, limiting use in high-burden settings. The QIAreach QuantiFERON-TB (QIAreach QFT) was developed to overcome these challenges but has not previously been evaluated in field conditions in a low-income, high-burden country, or at scale in children.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!